CD8A and neoplasm: When used as adjuvant for vaccination with tumor-associated antigens (TAAs) in a B cell lymphoma mouse model, IL-12 and IFN-γ production and an enhanced magnitude of the CD8+ T cell response were observed leading to an enhanced antitumor response (25).